FiercePharma

U.S. FDA Approves Bydureon® Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon® Pen (exenatide extended-release for injectable ...
Monthly Prescribing Reference

Bydureon BCise Gets FDA Approval for Type 2 Diabetes

In clinical trials, treatment with Bydureon BCise resulted in average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds when used as monotherapy or as an add-on to metormin, a ...
FiercePharma

BYDUREON™ Improved A1C, Fasting Glucose, Pulse Pressure and Weight Regardless of Baseline Body Weight in Patients with Type 2 Diabetes

PHILADELPHIA-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced results from an analysis of seven randomized clinical studies demonstrating that patients ...
Business Insider

BYDUREON® BCise™ Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes

WILMINGTON, Del., Jan. 10, 2018 /PRNewswire/ -- AstraZeneca today announced that BYDUREON ® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the ...
Daily Sundial

Bydureon Weight Loss Injection Review – Bydureon Bcise Exenatide Extended Release Alternatives Over the Counter

Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...
Business Wire

BYDUREON™ Was Associated with Significant and Sustained Glycemic Control at Four Years

BYDUREON was approved in the U.S. in January 2012 and in Europe in June 2011. BYDUREON is an injectable prescription medicine that may improve blood sugar (glucose) in adults with type 2 diabetes ...
The Financial

US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes

The FINANCIAL — AstraZeneca on October 23 announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of ...
Monthly Prescribing Reference

Bydureon Approved for Once-Weekly Treatment of Type 2 Diabetes

BYDUREON (exenatide extended-release for injectable suspension) 2mg/vial by Amylin and Alkermes Amylin and Alkermes announced that the FDA has approved Bydureon (exenatide extended-release for ...
FierceBiotech

BYDUREON™ Safety and Tolerability Pooled Summary Data Presented at ADA 2010

Data from Nearly 1,100 Patients in DURATION-1, -2 and -3 Trials Showed BYDUREON was Well-Tolerated ORLANDO, Fla.--(BUSINESS WIRE)-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company ...
FierceBiotech

BYDUREON™ FDA Action Date Set for January 28, 2012

SAN DIEGO, INDIANAPOLIS & WALTHAM, Mass.--(BUSINESS WIRE)-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the ...
Reuters

U.S. FDA approves Amylin's diabetes drug

WASHINGTON (Reuters) - Amylin Pharmaceuticals Inc won U.S. approval on Friday for its Bydureon diabetes drug, a long-awaited victory for the company's most promising product. After two delays, the ...